Dr. Reddy's Laboratories Limited has completed the divestment of its wholly owned subsidiary Svaas Wellness Limited for ₹2.23 crore. The pharmaceutical major announced the transaction completion on April 7, 2026, marking its exit from the wellness subsidiary business.

Transaction Details

The divestment involves the complete sale of Dr. Reddy's entire shareholding in Svaas Wellness Limited to Enspirited Technology Services Private Limited. The transaction was both agreed upon and completed on the same date, April 7, 2026.

Financial Impact

Svaas Wellness Limited's contribution to Dr. Reddy's overall business remained minimal. According to the FY 2025 audited financials, the subsidiary generated a turnover of ₹28.5 crore, with 100% of its revenue coming from Dr. Reddy's Laboratories Limited.

Buyer Profile and Transaction Nature

Enspirited Technology Services Private Limited, the acquiring entity, operates from Hyderabad with its registered office at Himayathnagar. The company is not affiliated with Dr. Reddy's promoter group or group companies, ensuring the transaction remains at arm's length.

The deal does not qualify as a related party transaction, as Enspirited Technology Services is not considered a related party to Dr. Reddy's or any of its subsidiaries. Following the completion of this divestment, Svaas Wellness Limited will cease to be a wholly owned subsidiary of Dr. Reddy's Laboratories.

Regulatory Compliance

The transaction disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Dr. Reddy's has provided comprehensive details as required under the regulatory framework, including buyer information, consideration amount, and transaction timeline.

This strategic divestment allows Dr. Reddy's to streamline its subsidiary portfolio while focusing on its core pharmaceutical operations. The minimal financial impact of ₹28.5 crore turnover suggests the company's decision to exit this non-core business segment aligns with its operational efficiency objectives.

Dr. Reddy's Laboratories has announced the allotment of 3,675 equity shares to eligible employees under its employee stock option plan on March 26, 2026. The pharmaceutical company issued these shares pursuant to the exercise of stock options under Dr. Reddy's Employees ADR Stock Options Scheme, 2007.

Share Allotment Details

The company allotted equity shares with a par value of Re.1/- each, fully paid up, to employees who exercised their stock options. The allotment was structured at two different price points based on the exercise terms.

Exercise Price Structure

The shares were issued under a tiered pricing structure reflecting different exercise prices for the stock options:

Impact on Share Capital

Following this allotment, Dr. Reddy's Laboratories' equity structure has been updated. The total issued shares after this allotment stands at 83,46,57,970, with the corresponding total issued share capital amounting to Rs. 83,46,57,970/-.

The newly allotted shares rank pari passu with existing equity shares and carry identical rights and privileges. The shares have been issued in dematerialized form under ISIN number INE089A01031, and no lock-in restrictions apply to these shares.

Regulatory Compliance

The allotment was made in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company has fulfilled all disclosure requirements under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and has notified all relevant stock exchanges where its shares are listed, including BSE Limited, National Stock Exchange of India Limited, New York Stock Exchange Inc., and NSE IFSC Limited.